Glabralide A is primarily investigated for its anti-inflammatory and immunomodulatory properties. It has shown potential in reducing pro-inflammatory cytokines, making it a candidate for development in treating chronic inflammatory conditions such as arthritis and inflammatory bowel disease. Research also indicates activity in inhibiting certain signaling pathways involved in autoimmune responses, suggesting possible use in autoimmune disorder therapies. Additionally, Glabralide A exhibits moderate antioxidant effects, which may contribute to cellular protection against oxidative stress. Its natural origin and biological activity profile support further exploration in pharmaceutical and dermatological applications, particularly in formulations aimed at skin inflammation and aging-related damage.